Login to Your Account



2010 American Society of Hematology Meeting

Celgene Slides on Revlimid Cancer Risk in Three Trials

By Trista Morrison


Tuesday, December 7, 2010
Of the 260 posters and presentations offered up by Celgene Corp. researchers during this year's American Society of Hematology (ASH) meeting, the biggest buzz surrounded blockbuster multiple myeloma drug Revlimid's potential to expand from second-line into front-line and maintenance use.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription